The Nontoxic Tripeptide Glycyl–Prolyl–Glycine Amide Inhibits the Replication of Human Immunodeficiency Virus Type 1
作者:
Jin Su,
Elin Andersson,
Peter Horal,
Mojgan Naghavi,
Anna Palm,
Yi-Pyng Wu,
Kristina Eriksson,
Marianne Jansson,
Hans Wigzell,
Bo Svennerholm,
Anders Vahlne,
期刊:
Journal of Human Virology
(OVID Available online 2001)
卷期:
Volume 4,
issue 1
页码: 1-7
ISSN:1090-9508
年代: 2001
出版商: OVID
关键词: Antiretrovirals against HIV;short peptides;glycyl-prolyl-glycine;HIV-1 laboratory strains;street strains;subtypes;drug resistance
数据来源: OVID
摘要:
ObjectiveTo determine whether short peptides corresponding to the RGPGR motif of the V3 loop of gp120 have anti-human immunodeficiency virus type 1 (anti–HIV-1) activity.Design/MethodsShort peptides were tested against the HIV-1 laboratory strains and clinical isolates.ResultsThe tripeptide glycyl–prolyl–glycine amide (GPG-NH2) inhibited the replication of both laboratory strains and 47 clinical isolates, including 19 strains that were resistant to other drugs or that were from patients with failing therapy. The 50% inhibitory concentrations values were 2.7 to 37 &mgr;M. Phenotypic change of two isolates from nonsyncytia-inducing to syncytia-inducing did not change their sensitivity to GPG-NH2. The tripeptide added to the antiviral effect of both zidovudine and ritonavir.ConclusionsThe tripeptide GPG-NH2is a nontoxic compound that inhibits the replication of HIV-1 by an apparently new mode of action. Glycyl–prolyl–glycine-NH2might prove useful by itself or as a lead compound for the treatment of drug-resistant HIV-1. Glycyl–prolyl–glycine-NH2is currently undergoing phase I/II human clinical trials in Sweden.
点击下载:
PDF
(232KB)
返 回